Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cara Therapeutics (CARA) PT Raised to $24 at H.C. Wainwright; 'Premier Partnership Incrementally De-Risks IV Korsuva'
May 23, 2018 12:44 PM EDTH.C. Wainwright raised its price target on Cara Therapeutics (NASDAQ: CARA) to $24.00 (from $22.00) while maintaining a Neutral rating.
... MoreCara Therapeutics (CARA) PT Raised to $20 at Stifel Following Vifor-Fresenius JV
May 23, 2018 11:01 AM EDTStifel raised its price target on Cara Therapeutics (NASDAQ: CARA) to $20.00 (from $17.00) while maintaining a Buy rating after the company announced a licensing arrangement with Vifor Fresenius Medical Care Renal Pharma (VFMCRP)a joint venture between Vifor Pharma (market leading provider of renal drugs) and... More
Cara Therapeutics (CARA) Bullish View Reiterated at Laidlaw Following Licence Agreement with Vifor Fresenius Medical
May 23, 2018 11:00 AM EDTLaidlaw analyst Francois Brisebois reiterated a Buy rating and $26 price target on Cara Therapeutics (NASDAQ: CARA) after the company announced that they have licensed worldwide rights (except US, Japan and South Korea) to commercialize Korsuva injection for the treatment of CKD-aP in dialysis patients to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
Brisebois commented, "We are encouraged by the financial implications of the licensing as CARA will receive an upfront... More
Needham & Company Maintains Bullish View on Cara Therapeutics (CARA) Following IV CR845 License Agreement
May 23, 2018 10:26 AM EDTNeedham & Company analyst Alan Carr reiterated a Buy rating and $23 price target on Cara Therapeutics (NASDAQ: CARA) after the company announced this morning a license and co-promotion agreement with Vifor Fresenius Medical Care Renal Pharma (VF).
Carr commented, "The agreement relates... More
